

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

Calu-6

RRID:CVCL_0236

Type: Cell Line

Proper Citation

RRID:CVCL_0236

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0236

Proper Citation: RRID:CVCL_0236

Description: Cell line Calu-6 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:1855224](#), [PMID:2388294](#), [PMID:3129183](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:3940644](#), [PMID:6148444](#), [PMID:6935474](#), [PMID:7459858](#), [PMID:7834619](#), [PMID:7972006](#), [PMID:8385084](#), [PMID:12068308](#), [PMID:12794755](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28273808](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Calu-6

Synonyms: CaLu-6, CALU-6, Calu.6, Calu 6, Calu6, CALU6, CaLu-06

Cross References: BTO:BTO_0002235, CLO:CLO_0002193, EFO:EFO_0002152, MCCL:MCC:0000125, CLDB:cl636, CLDB:cl638, ArrayExpress:E-MTAB-38,

ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-56, BioGRID_ORCS_Cell_line:587, BioSample:SAMN03473148, BioSample:SAMN10987791, cancercellines:CVCL_0236, CancerTools:161924, CCRID:1101HUM-PUMC000813, CCRID:3101HUMTCHu144, Cell_Model_Passport:SIDM00921, ChEMBL-Cells:ChEMBL3307639, ChEMBL-Targets:ChEMBL614535, CLS:300135, Cosmic:724859, Cosmic:929969, Cosmic:933575, Cosmic:934466, Cosmic:934542, Cosmic:1071885, Cosmic:1089230, Cosmic:1146874, Cosmic:1176611, Cosmic:1434959, Cosmic:1995360, Cosmic:2668262, Cosmic-CLP:724859, DepMap:ACH-000264, DSMZ:ACC-734, DSMZCellDive:ACC-734, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:724859, GEO:GSM108805, GEO:GSM108806, GEO:GSM253341, GEO:GSM434325, GEO:GSM513938, GEO:GSM514319, GEO:GSM794263, GEO:GSM817065, GEO:GSM843487, GEO:GSM886916, GEO:GSM887982, GEO:GSM1374435, GEO:GSM1374436, GEO:GSM1669659, IARC_TP53:119, IARC_TP53:21265, ICLC:HTL97003, IGRhCellID:Calu6, KCLB:30056, LiGeA:CCLE_215, LINCS_LDP:LCL-1626, Lonza:1139, NCBI_Iran:C431, PharmacDB:Calu6_180_2019, PRIDE:PXD025499, PRIDE:PXD030304, Progenetix:CVCL_0236, PubChem_Cell_line:CVCL_0236, Wikidata:Q54808427

ID: CVCL_0236

Record Creation Time: 20220427T215439+0000

Record Last Update: 20260913T002307+0000

Ratings and Alerts

No rating or validation information has been found for Calu-6.

No alerts have been found for Calu-6.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Cassese M, et al. (2026) LAT1/SLC7A5-mediated amino acid uptake is regulated by redox signals triggered by formyl-peptide receptor 2. The FEBS journal, 293(9), 2637.

Jakobsen JS, et al. (2026) Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(6), 1120.

Pan Y, et al. (2026) A covalent molecular glue hijacks the E3 ligase MKRN2 to degrade the ribosomal protein RPS7 and induce synthetic lethality in p53-deficient NSCLC cells. *British journal of pharmacology*.

Rouhimoghadam M, et al. (2026) Mechanistic dissection of SMARCA2/4 molecular glues reveals programmable switching between DCAF16 and FBXO22. *Cell chemical biology*.

Gebru MT, et al. (2025) Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer. *Cancer research*, 85(23), 4806.

Martínez Villarreal A, et al. (2025) Memory T-Cell Phenotype in Cutaneous T-Cell Lymphoma Is Modified by Germline Gene Gametocyte Specific Factor 1. *Experimental dermatology*, 34(5), e70123.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. *Cancer cell*.

Wang Y, et al. (2025) Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance. *Immunity*.

Kim JJ, et al. (2025) Discovery and characterization of a novel telomerase alternative splicing isoform that protects lung cancer cells from chemotherapy induced cell death. *Scientific reports*, 15(1), 6787.

Sagie S, et al. (2025) Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation. *Cell reports. Medicine*, 6(12), 102506.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Sun F, et al. (2024) Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. *eLife*, 12.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. *Cancer immunology research*, 12(4), 491.

Fukuda K, et al. (2024) Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. *Cell reports. Medicine*, 5(6), 101578.

Gantchev J, et al. (2023) Ectopically Expressed Meiosis-Specific Cancer Testis Antigen HORMAD1 Promotes Genomic Instability in Squamous Cell Carcinomas. *Cells*, 12(12).

Chen DY, et al. (2023) Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus. *iScience*, 26(5), 106634.

Kim JJ, et al. (2023) Dynamics of TERT regulation via alternative splicing in stem cells and cancer cells. *PloS one*, 18(8), e0289327.

Feng Y, et al. (2023) Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. *Cell reports*, 42(12), 113503.

Yamato M, et al. (2022) DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. *Molecular cancer therapeutics*, 21(4), 635.

Stribbling SM, et al. (2022) The cell-line-derived subcutaneous tumor model in preclinical cancer research. *Nature protocols*, 17(9), 2108.